FRAIL-M Study (AMaRC 19-01)
T he FRAIL-M study: Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM).
The FRAIL-M study is a stratified randomised controlled trial with aims to identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status (Fit, intermediate-fit and frail).
The finding from this study will provide a robust framework for optimisation of treatment in improved survival and preservation of quality of life (QoL) for Transplant Ineligible Myeloma Patients.
This study also seeks to inform more cost-effective utilisation of publicy funded high-cost front-line anti-MM therapeutics such as Bortezomib (Velcade®) and Lenalidomide (Revlimid®).
For more information
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Literature review, Research proposal, Ethics approval
Addition of sites for study recruitment
Medical Research Future Fund (MRFF)